Innate Pharma (IPHA) Competitors $2.23 0.00 (-0.18%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. NAGE, PHAR, AVBP, SANA, GYRE, OCS, DNA, ATAI, IMTX, and TNGXShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Immatics (IMTX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Tango Therapeutics Innate Pharma (NASDAQ:IPHA) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Do insiders and institutionals believe in IPHA or NAGE? 0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate IPHA or NAGE? Innate Pharma presently has a consensus target price of $11.00, suggesting a potential upside of 394.16%. Niagen Bioscience has a consensus target price of $13.42, suggesting a potential upside of 37.36%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Innate Pharma is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, IPHA or NAGE? Innate Pharma has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Does the media refer more to IPHA or NAGE? In the previous week, Niagen Bioscience had 10 more articles in the media than Innate Pharma. MarketBeat recorded 10 mentions for Niagen Bioscience and 0 mentions for Innate Pharma. Niagen Bioscience's average media sentiment score of 0.22 beat Innate Pharma's score of -1.00 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Innate Pharma Negative Niagen Bioscience Neutral Which has stronger valuation and earnings, IPHA or NAGE? Niagen Bioscience has higher revenue and earnings than Innate Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$21.77M9.43-$53.53MN/AN/ANiagen Bioscience$99.60M7.82$8.55M$0.2146.52 Is IPHA or NAGE more profitable? Niagen Bioscience has a net margin of 15.24% compared to Innate Pharma's net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Innate Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Niagen Bioscience 15.24%23.12%15.53% SummaryNiagen Bioscience beats Innate Pharma on 10 of the 15 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.19M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E RatioN/A20.3730.4325.14Price / Sales9.43238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book20.247.918.956.21Net Income-$53.53M-$54.72M$3.26B$265.38M7 Day Performance2.11%1.58%1.03%-1.12%1 Month Performance19.36%5.81%4.28%-0.68%1 Year Performance-1.50%8.71%28.38%18.92% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma1.9027 of 5 stars$2.25+0.9%$11.00+388.9%-4.9%$207.41M$21.77M0.00220Short Interest ↑NAGENiagen Bioscience1.3448 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.13M$116.30M48.19120PHARPharming Group1.9805 of 5 stars$12.39+6.4%$30.00+142.1%+56.3%$798.20M$297.20M-95.31280Gap UpAVBPArriVent BioPharma2.4321 of 5 stars$19.24-1.5%$39.14+103.4%-20.4%$792.31MN/A-4.7940Analyst UpgradeSANASana Biotechnology3.2358 of 5 stars$3.40+2.1%$8.00+135.3%-30.7%$791.90MN/A-3.21380GYREGyre Therapeutics0.1194 of 5 stars$7.85-3.6%N/A-34.1%$783.99M$102.19M785.7940OCSOculis3.1126 of 5 stars$18.06+0.9%$35.33+95.6%+46.5%$781.56M$780K-6.842News CoveragePositive NewsDNAGinkgo Bioworks0.8896 of 5 stars$13.79+4.6%$8.50-38.4%N/A$780.25M$227.04M-2.35640News CoverageATAIatai Life Sciences2.8389 of 5 stars$4.05+4.4%$11.25+177.8%+203.1%$777.31M$310K-5.8780Earnings ReportAnalyst RevisionIMTXImmatics1.9044 of 5 stars$6.21-1.9%$14.67+136.2%-52.3%$769.41M$168.65M-9.55260News CoverageAnalyst RevisionHigh Trading VolumeTNGXTango Therapeutics1.7174 of 5 stars$7.22+6.6%$10.33+43.1%-39.2%$753.23M$42.07M-5.4390Positive NewsAnalyst Forecast Related Companies and Tools Related Companies NAGE Alternatives PHAR Alternatives AVBP Alternatives SANA Alternatives GYRE Alternatives OCS Alternatives DNA Alternatives ATAI Alternatives IMTX Alternatives TNGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access